|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
82,625,000 |
Market
Cap: |
87.58(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.04 - $4.46 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
223,100 |
223,100 |
Total Sell Value |
$0 |
$0 |
$449,770 |
$449,770 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Viret Jean-Frederic |
Chief Financial Officer |
|
2021-02-01 |
4 |
AS |
$21.55 |
$159,513 |
D/D |
(7,402) |
61,295 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2021-02-01 |
4 |
OE |
$10.05 |
$74,390 |
D/D |
7,402 |
68,697 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2021-01-25 |
4 |
AS |
$19.00 |
$920,736 |
D/D |
(46,144) |
61,295 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2021-01-25 |
4 |
OE |
$10.05 |
$402,000 |
D/D |
40,000 |
107,439 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2021-01-19 |
4 |
AS |
$17.94 |
$44,852 |
D/D |
(2,500) |
59,739 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2021-01-19 |
4 |
OE |
$2.50 |
$6,251 |
D/D |
2,500 |
62,239 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2021-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
59,739 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2021-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
65,146 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2021-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
67,439 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2021-01-10 |
4 |
D |
$18.18 |
$74,174 |
D/D |
(4,080) |
36,189 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2021-01-10 |
4 |
D |
$18.18 |
$74,174 |
D/D |
(4,080) |
28,489 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2021-01-10 |
4 |
D |
$18.18 |
$74,174 |
D/D |
(4,080) |
33,896 |
|
- |
|
Mendelson Alan C |
Director |
|
2021-01-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,569 |
|
- |
|
Mendelson Alan C |
Director |
|
2021-01-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
Stolper Mark |
Director |
|
2021-01-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,800 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2020-12-17 |
4 |
AS |
$17.51 |
$43,780 |
D/D |
(2,500) |
32,569 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2020-12-17 |
4 |
OE |
$2.50 |
$6,251 |
D/D |
2,500 |
35,069 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2020-12-10 |
4 |
S |
$18.05 |
$318,066 |
D/D |
(17,626) |
36,673 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2020-12-10 |
4 |
OE |
$2.08 |
$36,729 |
D/D |
17,626 |
54,299 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2020-12-09 |
4 |
S |
$18.24 |
$903,084 |
D/D |
(49,512) |
36,673 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2020-12-09 |
4 |
OE |
$2.08 |
$62,514 |
D/D |
30,000 |
86,185 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2020-12-07 |
4 |
S |
$18.42 |
$161,896 |
D/D |
(8,791) |
32,569 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2020-12-07 |
4 |
OE |
$12.37 |
$110,656 |
D/D |
8,791 |
41,360 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2020-12-04 |
4 |
S |
$18.85 |
$923,694 |
D/D |
(49,000) |
32,569 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2020-12-04 |
4 |
OE |
$12.70 |
$753,079 |
D/D |
49,000 |
81,569 |
|
- |
|
312 Records found
|
|
Page 3 of 13 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|